Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Non Operating Income of -$790000.0 in Q1 2026, down 1195.08% quarter-over-quarter from -$61000.0 in Q4 2025, and down 1695.45% on a YoY basis from $49515.7 in Q1 2025.
Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non Operating Income history runs 10 years deep, the most recent figure standing at -$790000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 1695.45% year-over-year to -$790000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 69.61% YoY), while the FY2025 annual figure was -$301000.0, down 105.23% from the prior year.
- Non Operating Income was -$790000.0 for Q1 2026 at Scholar Rock Holding, down from -$61000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $2.9 million in Q4 2024 to a low of -$1.0 million in Q1 2022.
- Historically, Non Operating Income has averaged $700529.4 across 5 years, with a median of $990000.0 in 2024.
- The sharpest annual moves came in 2022 and 2026: Non Operating Income jumped 313.27% in 2022, then tumbled 1695.45% in 2026.
- A 5-year view of Non Operating Income shows it stood at $1.2 million in 2022, then jumped by 62.49% to $1.9 million in 2023, then surged by 52.31% to $2.9 million in 2024, then tumbled by 102.1% to -$61000.0 in 2025, then plunged by 1195.08% to -$790000.0 in 2026.
- The last three Non Operating Income figures came in at -$790000.0 (Q1 2026), -$61000.0 (Q4 2025), and -$69000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -790,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790,000.00 |
| Dec 31, 2025 | -61,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | -38,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 565,000.00 |
| Jun 30, 2022 | -853,000.00 |
| Mar 31, 2022 | -1.02 Mn |
| Dec 31, 2021 | -550,000.00 |
| Sep 30, 2021 | -430,000.00 |
| Jun 30, 2021 | -434,000.00 |